Printer Friendly

S&P RANKS ELAN TOP DRUG INDUSTRY EARNINGS PERFORMER; 10-YEAR RECORD SET

S&P RANKS ELAN TOP DRUG INDUSTRY EARNINGS PERFORMER; 10-YEAR RECORD SET
 NEW YORK, May 5 /PRNewswire/ -- Elan Corporation, plc (AMEX: ELN), today announced it has become the top earnings growth performer among U.S.-traded drug stocks, having today posted its fourth consecutive year of at least 100 percent earnings gains, according to Standard & Poor's Stock Guide data services. No other pharmaceutical firm has achieved that record in the last ten years.
 The S&P analysis also revealed that Elan is the first American Stock Exchange issue since 1986 to achieve four back-to-back years of such earnings growth, regardless of industry category.
 For its fiscal year ended March 31, 1992, the company reported $21.3 million in net profit, a gain of 102 percent over year-ago net of $10.4 million. In the two previous years, Elan's net was $5.19 million and $2.38 million, respectively.
 The S&P Stock Guide data base covers 5,300 U.S.-traded securities, 151 of which are in the pharmaceutical industry. About 875 companies trade on the American Stock Exchange.
 -0- 5/5/92
 /CONTACT: Brian Crotty of Elan, 800-252-3526; or Thomas Redington of Redington Inc., 203-222-7399 or 212-926-1733, for Elan/
 (ELN) CO: Elan Corporation plc ST: New York IN: MTC SU:


AH-GK -- NY070 -- 6581 05/05/92 12:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:220
Previous Article:DEUTSCHE BANK TO EXPAND IN U.S.
Next Article:LEXUS APRIL SALES MAINTAIN STRONG '92 PACE


Related Articles
ELAN CORPORATION ANNOUNCES RECORD PROFITS AS REVENUE PASSES THE $100 MILLION MILESTONE
ELAN COMMENTS ON SHARE PRICE DECLINE
ELAN STOCK SPLIT EFFECTIVE TOMORROW
ELAN STOCK SPLIT EFFECTIVE TOMORROW
ELAN ANNOUNCES NET INCOME INCREASE OF 63 PERCENT AND DRC BUYBACK
ELAN REPORTS FIRST QUARTER EARNINGS UP 69 PERCENT
ELAN CORPORATION AND DURA PHARMACEUTICALS ANNOUNCE SIGNING OF DEFINITIVE STOCK PURCHASE AGREEMENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters